Akero Therapeutics Inc (AKRO)

$20.51

-1.09

(-5.05%)

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Akero Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 48.8% return, outperforming this stock by 100.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 237.7% return, outperforming this stock by 262.0%

Performance

  • $20.45
    $21.45
    $20.51
    downward going graph

    0.29%

    Downside

    Day's Volatility :4.66%

    Upside

    4.38%

    downward going graph
  • $11.25
    $58.38
    $20.51
    downward going graph

    45.15%

    Downside

    52 Weeks Volatility :80.73%

    Upside

    64.87%

    downward going graph

Returns

PeriodAkero Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-1.41%
-0.7%
0.0%
6 Months
64.74%
7.7%
0.0%
1 Year
-51.52%
3.3%
-1.7%
3 Years
-24.26%
13.9%
-20.7%

Highlights

Market Capitalization
1.4B
Book Value
$9.6
Earnings Per Share (EPS)
-2.89
Wall Street Target Price
51.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-23.07%
Return On Equity TTM
-35.22%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-172.8M
Diluted Eps TTM
-2.89
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.97
EPS Estimate Next Year
-4.33
EPS Estimate Current Quarter
-0.86
EPS Estimate Next Quarter
-0.9

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Akero Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
14
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 148.66%

Current $20.51
Target $51.00

Technicals Summary

Sell

Neutral

Buy

Akero Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Akero Therapeutics Inc
Akero Therapeutics Inc
-20.66%
64.74%
-51.52%
-24.26%
11.95%
Moderna, Inc.
Moderna, Inc.
-2.96%
23.83%
-28.58%
-37.0%
331.65%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.23%
10.55%
10.52%
78.91%
167.64%
Novo Nordisk A/s
Novo Nordisk A/s
-6.56%
25.69%
48.76%
237.69%
410.4%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.23%
7.86%
19.8%
79.52%
133.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Akero Therapeutics Inc
Akero Therapeutics Inc
NA
NA
NA
-3.97
-0.35
-0.23
NA
9.6
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.8
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.3
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Akero Therapeutics Inc
Akero Therapeutics Inc
Buy
$1.4B
11.95%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.1B
331.65%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
167.64%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
410.4%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.49%
28.42
36.68%

Institutional Holdings

  • State Street Corporation

    7.43%
  • HHG PLC

    6.25%
  • BlackRock Inc

    6.06%
  • Alkeon Capital Management, LLC

    5.46%
  • T. Rowe Price Associates, Inc.

    5.33%
  • RTW INVESTMENTS, LLC

    5.21%

Corporate Announcements

  • Akero Therapeutics Inc Earnings

    Akero Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.

Organization
Akero Therapeutics Inc
Employees
55
CEO
Dr. Andrew Cheng M.D., Ph.D.
Industry
Health Technology

FAQs